新型雌激素受体GPER在乳腺癌组织中的表达及与预后的相关性  

No Correlation between Expression of GPER and Prognosis of Patients with Primary Breast Cancer

作　　者：罗平[1] 罗浩军[1] 杨光伦[1] 涂刚[1] 

机构地区：[1]重庆医科大学附属第一医院内分泌乳腺外科,重庆400016

出　　处：《肿瘤防治研究》2012年第2期181-184,共4页Cancer Research on Prevention and Treatment

基　　金：国家自然科学基金资助项目(30872520);教育部科学技术研究重点资助项目(208113);重庆市自然科学基金资助项目(CSTC;2008BB5200);重庆市教委科技资助项目(KJ080327)

摘　　要：目的探讨新型雌激素受体GPER在乳腺癌中的表达及与患者预后的关系。方法应用免疫组织化学SP法检测241例乳腺癌患者手术标本中GPER蛋白的表达,利用χ2检验和t检验分析其与临床病理变量的关系,结合随访资料利用生存函数分析其与患者预后的关系。结果乳腺癌组织中GPER阳性表达率为64.7%,其表达与ER、PR的表达显著相关(P<0.05),与HER-2及其他临床病理指标(年龄、月经情况、肿瘤大小、TNM分期、组织学分级、病理类型)无相关性(P>0.05)。中位随访时间44.6月,GPER阳性肿瘤患者无进展生存时间和总生存时间较阴性患者长,但差异无统计学意义(P>0.05)。GPER的表达与乳腺癌患者内分泌治疗耐药也无相关性(P>0.05)。结论 GPER在大部分乳腺癌中阳性表达,但对患者预后无显著影响,可能不是乳腺癌的独立预后因子。Objective To research the relationships between expression of G-protein coupled estrogen receptor（GPER） and patient prognosis in primary mammary cancers.Methods GPER from 241 tissues of primary breast cancer patients was detected by immunohistochemistry relationships between the expression of GPER and each of clinicopathological factors were analyzed by Chi-square and t-test.After a median 44.6 months follow-up,relationships between GPER expression and patient prognosis were analyzed by Kaplan-Meier method.Results GPER expression rate was 64.7%.There was a significant relationship among GPER and ERα,PR（P0.05）,while no statistically association between GPER and HER-2 as well as other clinicopathological variables（patients age,menstruation status,tumor size,TNM stage,histological grade and pathological type）（P0.05）.Disease-free survival and overall survival in patients with GPER＋ tumors were longer than those in patients with GPER-（P0.05）.There was no marked association between GPER expression and hormonal therapy resistance.Conclusion The expression of GPER was not significantly related with most clinicopathological variables and impact on prognosis of breast cancers patients,also not an independent prognostic determinant for breast carcinoma.

关 键 词：乳腺癌 雌激素受体 GPER 预后 

分 类 号：R737.9[医药卫生—肿瘤]